Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra in Post-AlloHCT Hypogammaglobulinemia
NCT03401268Completed
- Sponsor
- University Health Network
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in hypogammaglobulinemia, sponsored by University Health Network. Primary endpoint: Tolerability of home ScIG as replacement therapy at 6 months. Started Feb 2018; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
hypogammaglobulinemia
Beyond the preview
Go deeper on NCT03401268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401268.